We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agennix Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer
News

Agennix Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer

Agennix Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer
News

Agennix Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agennix Announces Issuance of European Patent Covering Use of Talactoferrin to Treat Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agennix AG has announced that the European Patent Office has issued patent number 1507554, entitled, "Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases," covering the use of oral human lactoferrins, including talactoferrin, to treat cancer.

It also covers the use of talactoferrin in combination with other therapies, including chemotherapy, immunotherapy, radiation therapy and other treatments. The patent has a term until 2023.

Torsten Hombeck, Ph.D., Spokesperson of the Management Board and Chief Financial Officer, said: "This patent further strengthens our intellectual property position for talactoferrin in the area of oncology. This European patent provides broad protection for talactoferrin in this key market, as it covers the use of human lactoferrin for oral administration, used alone or in combination with other therapies, for the treatment of all cancer types. We also have cancer use patents that were recently issued in the U.S. and Japan, two of the other major markets for talactoferrin, that provide protection until 2025 and 2023, respectively, and include coverage for our lead indication, non-small cell lung cancer."

Advertisement